Study of FKC289 for AL amyloidosis that has returned or not responded
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new treatment called FKC289 for people with AL amyloidosis that has come back or not responded to prior therapy. It aims to see if the drug is safe and effective in clearing abnormal proteins and improving organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have a confirmed diagnosis of primary light chain (AL) amyloidosis
- Your disease has come back or hasn't responded to earlier treatments
- You have a certain level of abnormal protein in your blood (dFLC ≥ 40 mg/L)
- You are generally well enough to carry out daily activities (ECOG score 0-2)
- You have not had a recent active infection or certain serious medical conditions (like heart disease or organ transplant)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called FKC289 for people whose membranous nephropathy (a kidney condition where the immune system attacks the kidney's filters) has come back or not improved with other treatments. The goal is to see if FKC289 is safe and can reduce protein in the urine, which indicates how well the kidney is working.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
This trial tests a new injection called CM336 for people with light-chain amyloidosis that has come back or not responded to other treatments. It aims to see if the drug is safe and effective.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
Hear when a new Primary Light Chain (AL) Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.